Emerging Fungal Infections

On this page

Intro & Drivers - The Rising Tide

  • Emerging Fungal Infections (EFIs): Infections newly appeared, rapidly ↑ incidence/geographic range, or evolved/drug-resistant.

  • Global Health Threat: ↑ morbidity & mortality, esp. in immunocompromised.

  • Key Drivers:

    • ↑ Immunocompromised populations (HIV, transplants, biologics)
    • Climate change & environmental factors
    • ↑ Use of broad-spectrum antifungals → resistance
    • International travel & trade
    • Improved diagnostic capabilities

Candida auris is a multi-drug resistant yeast that can cause invasive infections and is difficult to identify with standard laboratory methods, posing a significant nosocomial threat worldwide.

Key Pathogens - Fungal Foes

  • Candida auris (C. auris)

    • Multidrug-resistant (MDR) yeast; causes healthcare-associated infections (HAIs), outbreaks.
    • Difficult to identify with standard lab methods; high mortality.
    • Transmission: Contact with contaminated surfaces or infected individuals.
    • 📌 Auris Usually Resists Infection Solutions.
  • Cryptococcus gattii (C. gattii)

    • Infects immunocompetent individuals, unlike C. neoformans.
    • Associated with eucalyptus trees; causes pulmonary & CNS infections (cryptococcomas).
    • Requires prolonged treatment.
  • Azole-Resistant Aspergillus fumigatus (ARAf)

    • Global threat; resistance via cyp51A mutations (e.g., TR34/L98H).
    • Acquired environmentally (agricultural azoles) or in-host.
    • ↑ mortality in invasive aspergillosis (immunocompromised).
    • Susceptibility testing crucial.

Candida auris yeast cells: DIC, SEM, and TEM views

Candida auris can persist on dry surfaces in healthcare settings for several weeks, contributing significantly to its transmission and outbreak potential, making stringent environmental disinfection critical for control.

Diagnosis - Fungal Fingerprints

  • Microscopy: Rapid visualization (KOH, Calcofluor White, India Ink); provides initial morphological clues, guides further testing.
  • Culture: Gold standard (SDA, specialized media); allows species identification, Antifungal Susceptibility Testing (AFST). Challenges: slow growth, some organisms are fastidious.
  • Histopathology: Biopsy with special stains (PAS, GMS); confirms tissue invasion and shows fungal morphology in situ.
  • Serology (Non-Culture Based):
    • (1,3)-β-D-Glucan (BDG): Broad pan-fungal marker (serum/CSF).
    • Specific Antigens: e.g., Galactomannan (Aspergillus), Cryptococcal Antigen (CrAg) (Cryptococcus).
  • Molecular Methods: PCR (panfungal/species-specific), sequencing (e.g., ITS region); vital for rare, novel, or unculturable fungi.
  • MALDI-TOF MS: Rapid proteomic identification from culture isolates; accuracy dependent on comprehensive databases.
  • AFST: Essential for guiding appropriate therapy and monitoring emerging resistance patterns.

⭐ (1,3)-β-D-Glucan (BDG) is a key pan-fungal marker, but typically negative in Mucormycosis and may be low/negative in Cryptococcosis.

Management & Resistance - Battle Tactics

  • Principles: Early diagnosis, source control, antifungal stewardship, immune support.
  • Antifungals & Resistance:
    • Azoles (Vori, Posa, Isavu): Inhibit ergosterol synthesis. Resist: ERG11 mutation, efflux.
    • Echinocandins (Caspo, Mica): Inhibit glucan synthesis. Resist: FKS mutations.

      Candida auris often shows multidrug resistance (MDR); susceptibility testing is crucial.

    • Polyenes (AmB): Bind ergosterol. Resist: Rare, ergosterol changes.
    • 5-FC: DNA/RNA inhibitor. Rapid solo resistance.
  • Pathogen Tactics:
    • C. auris: Echinocandins first; L-AmB if resistant. Strict infection control.
    • Azole-R Aspergillus: L-AmB, Vori/Isavu (if susceptible).
    • Mucormycosis: Surgery + L-AmB (3-5 mg/kg/day, up to 10 mg/kg/day).
  • Prevention: Prophylaxis (high-risk), surveillance, environmental hygiene. ​

High‑Yield Points - ⚡ Biggest Takeaways

  • Candida auris: A multidrug-resistant (MDR) yeast causing nosocomial outbreaks; difficult to identify.
  • Mucormycosis: Surged post-COVID-19, especially in uncontrolled diabetics; classic rhino-orbital-cerebral presentation.
  • Cryptococcus gattii: Notably infects immunocompetent individuals, unlike C. neoformans.
  • Azole-resistant Aspergillus fumigatus: A significant and emerging threat.
  • Fusarium spp.: Cause fungal keratitis (contact lens use) and infections in the immunocompromised.
  • Scedosporium spp.: Associated with near-drowning and often Amphotericin B resistant.

Practice Questions: Emerging Fungal Infections

Test your understanding with these related questions

Which antifungal binds to ergosterol, causing fungal cell membrane damage?

1 of 5

Flashcards: Emerging Fungal Infections

1/8

_____ is commonly found growing on heroin.IV injection of the drug can therefore lead to candidal endocarditis

Hint: which fungus

TAP TO REVEAL ANSWER

_____ is commonly found growing on heroin.IV injection of the drug can therefore lead to candidal endocarditis

Candida albicans

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial